Much is riding on Travere Therapeutics’ bid to gain an expansion for Filspari to treat focal segmental glomerulosclerosis ...

Travere Therapeutics recently reported that the FDA has extended its review of the supplemental New Drug Application for ...

Travere Therapeutics shares crashed Tuesday as investors digested a potential delay for its drug, Filspari, in treating a ...

Travere Therapeutics, Inc., (Nasdaq: TVTX) announced that today the U.S. Food and Drug Administration (FDA) has extended the review timeline of its supplemental New Drug Application (sNDA) for ...

Shares of Travere Therapeutics TVTX were down 14.6% on Tuesday after the company announced that the FDA had extended the ...

The U.S. Food and Drug Administration has extended its review for the expanded ​use of Travere Therapeutics’ drug to treat a ...

Travere Therapeutics FY25 sales surged on Filspari, but the FDA FSGS label decision was delayed to April. Click here to read ...

Zane was just 15 months old when his parents noticed something wasn’t right. His eyes, legs and belly were very swollen. At first, it seemed like allergies. As soon as the pediatrician saw Zane, he ...

Translational medicine researchers used the Mimetas® human kidney glomerulus-on-a-chip to investigate potential pharmaceutical interventions for patients with a severe kidney disease called focal ...

Food and Drug Administration ​has extended its review for ‌the expanded use of Travere Therapeutics’ ‌drug to treat a type of ...